Which Head and Neck Cancer Data Should You Watch For at ESMO 2026?

The European Society for Medical Oncology (ESMO) Congress 2026, held October 23 to 27 in Madrid, Spain, will feature several data sets that may shape the future of head and neck squamous cell carcinoma (HNSCC) management. Among them are early first-line results for an EGFR/MET bispecific antibody regimen, a novel bispecific antibody-drug conjugate (ADC) paired with immunotherapy, an induction strategy ahead of definitive chemoradiation, and a randomized test of OX40 agonism. Jong Chul Park, MD, a medical oncologist at the Center for Head and Neck Cancers at Mass General Brigham, spoke with CancerNetwork® about 4 abstracts that healthcare professionals involved in the care of patients with HNSCC should be watching.